CLINICAL_TRIALS
trial_result
· 2012-12-04
Clinical Trial Update: Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients [Phase 2]
Summary
Phase 2 dose-finding study of ofatumumab in relapsing-remitting multiple sclerosis completed; results were posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2012-12-04